Replimune Group, Inc. (REPL)
Largest Insider Buys in Sector
REPL Stock Price History Chart
REPL Stock Performance
About Replimune Group, Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing …
Insider Activity of Replimune Group, Inc.
Over the last 12 months, insiders at Replimune Group, Inc. have bought $0 and sold $981,942 worth of Replimune Group, Inc. stock.
On average, over the past 5 years, insiders at Replimune Group, Inc. have bought $17.97M and sold $15.97M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,100,000 shares for transaction amount of $14.97M was made by Rhodes Jason P (director) on 2019‑11‑18.
List of Insider Buy and Sell Transactions, Replimune Group, Inc.
| 2024-08-16 | Sale | Chief Financial Officer | 8,938 0.0137% | $10.18 | $90,989 | 0.00% | ||
| 2024-06-07 | Sale | Chief Medical Officer | 15,881 0.0245% | $7.50 | $119,108 | +31.77% | ||
| 2024-05-16 | Sale | director | 11,464 0.0189% | $6.47 | $74,172 | +52.75% | ||
| 2024-05-16 | Sale | Executive Chairman | 37,928 0.0626% | $6.47 | $245,394 | +52.75% | ||
| 2024-05-16 | Sale | Chief Operating Officer | 17,615 0.0291% | $6.47 | $113,969 | +52.75% | ||
| 2024-05-16 | Sale | Chief Executive Officer | 20,194 0.0333% | $6.47 | $130,655 | +52.75% | ||
| 2024-05-16 | Sale | Chief Medical Officer | 6,367 0.0105% | $6.47 | $41,194 | +52.75% | ||
| 2024-05-16 | Sale | Chief Commercial Officer | 2,218 0.0037% | $6.47 | $14,350 | +52.75% | ||
| 2024-05-16 | Sale | Chief Accounting Officer | 2,298 0.0038% | $6.47 | $14,868 | +52.75% | ||
| 2023-11-16 | Sale | Chief Medical Officer | 7,313 0.0131% | $10.92 | $79,858 | -17.41% | ||
| 2023-11-16 | Sale | Chief Commercial Officer | 5,255 0.0094% | $10.92 | $57,385 | -17.41% | ||
| 2023-09-12 | Sale | Chief Business Officer | 300 0.0005% | $20.00 | $6,000 | -55.11% | ||
| 2023-09-11 | Sale | Chief Business Officer | 5,358 0.0092% | $20.01 | $107,214 | -56.49% | ||
| 2023-08-22 | Sale | Chief Business Officer | 18,600 0.0315% | $20.01 | $372,186 | -56.96% | ||
| 2023-08-11 | Sale | Chief Business Officer | 1,400 0.0024% | $20.00 | $28,000 | -56.52% | ||
| 2023-07-10 | Sale | Chief Business Officer | 20,000 0.035% | $21.58 | $431,541 | -58.52% | ||
| 2023-06-13 | Sale | Chief Strategy Officer | 5,698 0.0098% | $24.05 | $137,008 | -62.70% | ||
| 2023-06-13 | Sale | Chief Dev. Op. Officer | 12,860 0.0221% | $24.06 | $309,395 | -62.70% | ||
| 2023-05-16 | Sale | President & Chief R&D Officer | 7,861 0.0132% | $18.05 | $141,891 | -39.43% | ||
| 2023-05-16 | Sale | Chief Executive Officer | 17,902 0.03% | $18.05 | $323,131 | -39.43% |
Insider Historical Profitability
| Omega Fund IV, L.P. | 4763380 6.972% | $12.55 | 2 | 20 | +27.98% | |
| Slootweg Hugo Alexander | 4721449 6.9106% | $12.55 | 1 | 0 | <0.0001% | |
| Forbion Capital Fund III Cooperatief U.A. | 10 percent owner | 4721449 6.9106% | $12.55 | 1 | 0 | <0.0001% |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2838968 4.1553% | $12.55 | 1 | 0 | <0.0001% |
| Rhodes Jason P | director | 946000 1.3846% | $12.55 | 1 | 11 | +63.12% |
Institutional Investor Ownership
| Baker Bros Advisors LP | $77.99M | 14.23 | 9.55M | 0% | +$0 | 0.56 | |
| T. Rowe Price | $53.51M | 9.76 | 6.55M | +11.96% | +$5.72M | 0.01 | |
| State Street | $53M | 9.67 | 6.49M | +26.9% | +$11.24M | <0.01 | |
| BlackRock | $37.68M | 6.88 | 4.61M | +1.63% | +$605,160.07 | <0.01 | |
| Redmile Group | $30.47M | 5.56 | 3.73M | -3.5% | -$1.11M | 0.31 |